Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP)

Vista sencilla de ítem
dc.contributor.authorHeredia, David
dc.contributor.authorBarrón-Barrón, Feliciano
dc.contributor.authorCardona, Andrés Felipe
dc.contributor.authorCampos, Saul T.
dc.contributor.authorRodríguez-Cid, Jerónimo Rafael
dc.contributor.authorMartínez-Barrera, Luis Manuel
dc.contributor.authorAlatorre, Jorge
dc.contributor.authorSalinas, Miguel Ángel
dc.contributor.authorLara-Mejía, Luis
dc.contributor.authorFlores-Estrada, Diana
dc.contributor.authorArrieta, Oscar
dc.contributor.orcidCardona, Andrés Felipe [0000-0003-3525-4126]
dc.date.accessioned2021-04-14T20:16:02Z
dc.date.available2021-04-14T20:16:02Z
dc.date.issued2021-01
dc.description.abstractenglishBackground: Brigatinib has demonstrated its efficacy as first-line therapy and in further lines for ALK-positive non-small cell lung cancer (NSCLC) patients; however, real-world data in Latin America are scarce. Methods: From January 2018 to March 2020, 46 patients with advanced ALK-positive NSCLC received brigatinib as second or further line of therapy in Mexico and Colombia. The primary end point was progression-free survival (PFS); secondary end point was time to treatment discontinuation (TTD). Results: At a median follow-up of 9.3 months, the median PFS was 15.2 months (95% CI: 11.6-18.8), and TTD was 18.46 months (95% CI: 9.54-27.38). The estimated overall survival at 12 months was 80%. Safety profile was consistent with previously published data. Conclusion: Brigatinib is an effective treatment for previously treated ALK-positive NSCLC patients in a real-world setting.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.2217/fon-2020-0747
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1744-8301
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/5776
dc.language.isoeng
dc.publisherFuture Medicine Ltd.spa
dc.publisher.journalFuture Oncologyspa
dc.relation.ispartofseriesFuture Oncology, 1744-8301, Vol. 17, Nro.2, 2021, p. 169-181spa
dc.relation.urihttps://www.futuremedicine.com/doi/10.2217/fon-2020-0747?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.localAcceso abiertospa
dc.subject.keywordsAnaplastic lymphoma kinasespa
dc.subject.keywordsBrigatinibspa
dc.subject.keywordsCeritinibspa
dc.subject.keywordsCrizotinibspa
dc.subject.keywordsEarly accessspa
dc.subject.keywordsLung cancerspa
dc.subject.keywordsNon-small cell lung cancerspa
dc.subject.keywordsReal-world evidencespa
dc.titleBrigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP)spa
dc.title.translatedBrigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP)spa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
David Heredia, Feliciano Barrón, Andrés F. Cardona_2021.pdf
Tamaño:
1.76 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos